Marksans Pharma is currently trading at Rs. 53.85, up by 1.70 points or 3.26 % from its previous closing of Rs. 52.15 on the BSE.
The scrip opened at Rs. 53.00 and has touched a high and low of Rs. 55.80 and Rs. 52.10 respectively. So far 2375690 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 58.30 on 04-Oct-2016 and a 52 week low of Rs. 36.95 on 01-Feb-2017.
Last one week high and low of the scrip stood at Rs. 54.40 and Rs. 47.00 respectively. The current market cap of the company is Rs. 2230.76 crore.
The promoters holding in the company stood at 48.25%, while institutions and non-institutions held 14.54% and 37.21% respectively.
Marksans Pharma manufacturing facility at Verna, Goa has been audited by the United States Food and Drug Administration (USFDA) from April 3-7, 2017. At the end of the inspection, there were 4 observations given under form 483. The company has already started addressing the same and is confident of satisfying the FDA within the stipulated time.
Further, the USFDA has also granted final approval of the Abbreviated New Drug Application for Dutasteride Soft Gelatin Capsules 0.5 mg, which is therapeutically equivalent to the reference listed drug (RLD), Avodart Capsules, 0.5 mg of GlaxoSmithKline. Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. The company will launch the product immediately.
Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.70 |
Dr. Reddys Lab | 5907.00 |
Cipla | 1375.90 |
Zydus Lifesciences | 990.00 |
Lupin | 1645.80 |
View more.. |